Hormonal
In patients with type 2 diabetes and diabetic kidney disease (specifically macroalbuminuria A3), subcutaneous semaglutide significantly reduces albuminuria and improves glycemic control (HbA1c) over a 6-month period, while showing no statistically significant impact on blood pressure, weight, or estimated glomerular filtration rate (eGFR).
For patients with diabetes and kidney disease, semaglutide is an effective treatment to lower blood sugar and reduce kidney stress (albuminuria), even if it doesn't significantly change weight or blood pressure in the short term. It is safe and should be considered, especially for those with high albumin levels.
Se encontró una significancia estadística en la disminución de la HbA1c... y... una disminución estadísticamente significativa con mediana a los tres meses... y a los seis meses... p = 0,0060. No se obtuvieron resultados estadísticamente significativos en cuanto a la mejoría de la presión arterial (PA), el peso y el control de lípidos.
Why this rating
Observational retrospective study with a small sample size (n=30) and short duration (6 months), limiting generalizability compared to large RCTs.
Source
Semaglutida en enfermedad renal diabética: Experiencia en dos programas de salud renal en Colombia
Rodrigo Daza-Arnedo et al. · Revista Colombiana de Endocrinología Diabetes & Metabolismo · 2022
DOI 10.53853/encr.9.3.776
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →